Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author exact FBC71966-F0ED-11E1-A9DE-61C894A0A6B4 cql: author exact 1E3B12E0-F0EE-11E1-A9DE-61C894A0A6B4

Add to list
Microbiome and metabolome dynamics during radiotherapy for prostate cancer

Willeke Danckaert (UGent) , Mathieu Spaas (UGent) , Nora Sundahl, Aurélie De Bruycker (UGent) , Valerie Fonteyne (UGent) , Ellen De Paepe (UGent) , Carlos De Wagter (UGent) , Lynn Vanhaecke (UGent) and Piet Ost (UGent)

(2023) RADIOTHERAPY AND ONCOLOGY. 189.
Add to list
Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors : the CHEERS phase 2 randomized clinical trial

Mathieu Spaas (UGent) , Nora Sundahl, Vibeke Kruse (UGent) , Sylvie Rottey (UGent) , Daan De Maeseneer (UGent) , Fréderic Duprez (UGent) , Yolande Lievens (UGent) , Veerle Surmont (UGent) , Lieve Brochez (UGent) , Dries Reynders (UGent) , et al.

(2023) JAMA ONCOLOGY. 9(9). p.1205-1213
Add to list
- Conference Paper
- C3
Immuno-radiotherapy in solid tumors : preliminary results of the randomized phase 2 CHEERS trial

Mathieu Spaas (UGent) , Nora Sundahl, Sylvie Rottey (UGent) , VIBEKE KRUSE (UGent) , Daan De Maeseneer (UGent) , Fréderic Duprez (UGent) , Piet Dirix, Veerle Surmont (UGent) , Yolande Lievens (UGent) , Robin Van den Begin, et al.

(2021) ESTRO 2021, Abstracts. 161(S1). p.S490-S491
Add to list
- Journal Article
- A1
- open access
Clinical relevance of serum Kyn/Trp ratio and basal and IFN gamma-upregulated IDO1 expression in peripheral monocytes in early stage melanoma

Annabel Meireson (UGent) , Liesbeth Ferdinande (UGent) , Marc Haspeslagh (UGent) , Benjamin Hennart, Delphine Allorge, Piet Ost (UGent) , Nora Sundahl, Mathieu Spaas (UGent) , Annelies Demeyer (UGent) and Lieve Brochez (UGent)

(2021) FRONTIERS IN IMMUNOLOGY. 12.
Add to list
- Journal Article
- A1
- open access
Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures

Annabel Meireson (UGent) , Simon Tavernier (UGent) , Sofie Van Gassen (UGent) , Nora Sundahl, Annelies Demeyer (UGent) , Mathieu Spaas (UGent) , Vibeke Kruse (UGent) , Liesbeth Ferdinande (UGent) , Jo Van Dorpe (UGent) , Benjamin Hennart, et al.

(2021) CANCERS. 13(11).
Add to list
- Journal Article
- A1
- open access
Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS) : study protocol for a phase 2, open-label, randomized controlled trial

Mathieu Spaas (UGent) , Nora Sundahl, Eva Hulstaert, Vibeke Kruse (UGent) , Sylvie Rottey (UGent) , Daan De Maeseneer (UGent) , Veerle Surmont (UGent) , Annabel Meireson (UGent) , Lieve Brochez (UGent) , Dries Reynders (UGent) , et al.

(2021) BMC CANCER. 21(1).
Add to list
Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma

Nora Sundahl, Teofila Seremet, Jo Van Dorpe (UGent) , Bart Neyns, Liesbeth Ferdinande, Annabel Meireson (UGent) , Lieve Brochez (UGent) , Vibeke Kruse (UGent) and Piet Ost (UGent)

(2019) INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. 104(4). p.828-835
Add to list
Randomized phase 1 trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results

Piet Ost (UGent) , Nora Sundahl, G Vandekerkhove, Karel Decaestecker (UGent) , Annabel Meireson (UGent) , Pieter De Visschere (UGent) , Valerie Fonteyne (UGent) , Daan De Maeseneer (UGent) , Dries Reynders (UGent) , Els Goetghebeur (UGent) , et al.

(2019) EUROPEAN UROLOGY SUPPLEMENTS. 18(1). p.e2105-e2105
Add to list
- Conference Paper
- C3
Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma : clinical and translational results

Gillian Vandekerkhove, Nora Sundahl, Karel Decaestecker (UGent) , Annabel Meireson (UGent) , Pieter De Visschere (UGent) , Valerie Fonteyne (UGent) , Daan De Maeseneer (UGent) , Dries Reynders (UGent) , Els Goetghebeur (UGent) , Jo Van Dorpe (UGent) , et al.

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(7, suppl. 5).
Add to list
Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma

Nora Sundahl, Gillian Vandekerkhove, Karel Decaestecker (UGent) , Annabel Meireson (UGent) , Pieter De Visschere (UGent) , Valerie Fonteyne (UGent) , Daan De Maeseneer (UGent) , Dries Reynders (UGent) , Els Goetghebeur (UGent) , Jo Van Dorpe (UGent) , et al.

(2019) EUROPEAN UROLOGY. 75(5). p.707-711

Academic Bibliography

Microbiome and metabolome dynamics during radiotherapy for prostate cancer

Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors : the CHEERS phase 2 randomized clinical trial

Immuno-radiotherapy in solid tumors : preliminary results of the randomized phase 2 CHEERS trial

Clinical relevance of serum Kyn/Trp ratio and basal and IFN gamma-upregulated IDO1 expression in peripheral monocytes in early stage melanoma

Immune monitoring in melanoma and urothelial cancer patients treated with anti-PD-1 immunotherapy and SBRT discloses tumor specific immune signatures

Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS) : study protocol for a phase 2, open-label, randomized controlled trial

Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma

Randomized phase 1 trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results

Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma : clinical and translational results

Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma

Contents

Support

Contact